Oxford BioDynamics (GB:OBD) has released an update.
Oxford BioDynamics will showcase its EpiSwitch platform at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics, emphasizing its utility in cancer immunotherapy. The company’s keynote will cover diagnostic and prognostic tests, including the EpiSwitch CiRT for predicting patient responses to immunotherapy, and the EpiSwitch HiRT for identifying patients at risk of hyperprogressive disease. Additionally, they will discuss the application of their large-scale data knowledgebase and AI algorithms in the development of multiplex assays for early diagnosis and management of immunotherapy-related adverse events.
For further insights into GB:OBD stock, check out TipRanks’ Stock Analysis page.
